NY-DILIGENT
15.2.2024 14:01:32 CET | Business Wire | Press release
In 2023, 982 companies were subject to activist campaigns globally, a 4.6% rise compared to a year prior and the highest level since 2019. This is according to the new Diligent Market Intelligence: Shareholder Activism Annual Review 2024 report from Diligent. The findings were released live today at Diligent’s first annual Proxy Season Preview, a leading proxy season conference featuring panels and keynote speeches from the world’s most prominent stewardship specialists on topics including shareholder activism, environmental, social and governance (ESG), executive compensation and more.
According to the report, more companies are identifying activism as a risk in their corporate disclosures. In 2023, 23.4% of Russell 3000 companies disclosed shareholder activism as a risk in their 10-K reporting, up from 21.4% a year prior. Financial resilience and the introduction of the universal proxy card are driving both traditional and nontraditional activists to launch campaigns aimed at remuneration and ESG oversight.
“Market conditions are playing a notable role in shaping activist demands and the companies which activists choose to target,” said Josh Black, editor-in-chief of Diligent Market Intelligence, at Diligent. “Now more than ever, boards need to demonstrate that they are financially resilient and have strong governance practices in place to stay one step ahead.”
Three themes emerge from the report’s key findings that both boards and investors should have on their radar. These include:
Activism goes global as shareholders look to maximize returns:
- In 2023, 550 U.S. companies were publicly subjected to activist demands, a 7.8% rise compared to a year prior, with many campaigns taking aim at costly M&A transactions. The U.S. saw a 20.8% increase in the number of companies subjected to oppose M&A demands, from 24 to 29.
- 220 Asia-based companies were subject to demands in 2023, marking the third consecutive year of increasing campaigns in the region while, in Canada, 69 companies were subjected to demands a 25.5% increase compared to 2022.
- Meanwhile, shareholder activism stagnated in Europe, with 123 European companies publicly subjected to campaigns in 2023, down from a high of 177 in 2021. However, the number of board seats activists secured held steady at 36 in 2023 compared to 38 in 2022, indicating that activists are continuing to push for board representation in Europe.
Market volatility prompts increase in remuneration demands:
- Investors enhanced their focus on remuneration in 2023, keen to ensure companies have robust policies and practices in place to weather market risks. In the U.S., 81 companies faced remuneration-related demands, a 37.3% increase compared to the 59 seen in 2022 and the highest increase of any demand type.
- Shareholder proposals concerning pay are also winning increased backing. Three proposals seeking clawback policy amendments won 36.5% average support at U.S.-based companies, up from five winning 27.5% support a year prior.
Universal proxy provides an avenue for non-traditional activists to launch ESG campaigns:
- The number of ESG demands publicly made by primary- and partial-focus activists increased in 2023 to 132 demands globally, up from 114 demands a year prior, and almost double the 79 seen in 2021.
- In the U.S., the newfound freedom universal proxy offers when casting votes is bringing forth non-traditional activists, seeking board composition changes to remedy ESG shortcomings.
To download the full report, produced in association with Olshan Frome Wolosky, click here.
About the report
Data from Diligent Market Intelligence’s Activism, Voting and Shorts modules run from January 1, 2023, to December 31, 2023. Further data is available on request, although bespoke analysis may take 48 hours. For more information, please email dmi.press@diligent.com
About Diligent Market Intelligence
Diligent Market Intelligence (DMI) is a market-leading provider of shareholder activism, investor voting, and corporate governance data. Through its web application and data feeds, clients can access the most complete solution for listed company intelligence on the market, with broader and deeper insights than ever before.
About Diligent
Diligent is the leading GRC SaaS company, empowering more than 1 million users and 700,000 board members and leaders to make better decisions, faster. The Diligent One Platform helps organizations connect their entire GRC practice — including governance, risk, compliance, audit and ESG — to bring clarity to complex risk, stay ahead of regulatory changes and deliver impactful insights, in one consolidated view. Learn more at diligent.com.
Follow Diligent on LinkedIn, X (Twitter) and Facebook.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240215609851/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ILiAD Biotechnologies Expands BPZE1 Public Health and Commercial Potential with Publication of Pediatric Phase 2b Study in The Lancet Infectious Diseases2.10.2026 14:00:00 CEST | Press release
Intranasal pertussis vaccine candidate BPZE1 demonstrates robust nasal mucosal and systemic immune responses with a favorable safety profile in children ages 6 through 17 yearsFirst pediatric clinical trial builds on 5 prior adult BPZE1 clinical studiesDemonstrates safety and immunogenicity of BPZE1 in acellular pertussis vaccine primed individualsNo interference observed when BPZE1 co-administered with diphtheria and tetanus antigens ILiAD Biotechnologies, Inc. (ILiAD), an advanced clinical stage biotech company focused on the prevention and treatment of disease caused by Bordetella pertussis, today announced the publication of results from its Phase 2b SUPER (Stand Up to Pertussis) clinical trial in The Lancet Infectious Diseases. This randomized, double blind, placebo- and active-comparator-controlled trial demonstrated that BPZE1, a live attenuated intranasal pertussis vaccine, induced robust nasal mucosal immune responses in healthy children aged 6 through 17 years (LINK). The stu
NIQ Brings New AI and Automation Capabilities to Retail Space Planning and Merchandising2.10.2026 12:45:00 CEST | Press release
New AI and automation capabilities help retailers close execution gaps and scale merchandising decisions across every store. NielsenIQ (NYSE: NIQ), a leading consumer intelligence company, today announced new AI and automation capabilities for NIQ Spaceman®, its retail space planning and merchandising platform trusted by more than 600 retailers across 65+ countries. The enhancements help retailers create store-specific planograms up to 50 times faster, identify execution and compliance gaps, and scale merchandising decisions across their store networks through expanded cloud-based access. "Retailers are under increasing pressure to localize assortments, execute consistently across stores, and respond more quickly to changing shopper behavior," said Natalie Williams, SVP, Product at NIQ. "These enhancements help simplify that process by embedding agentic AI directly into merchandising workflows and automating traditionally manual planning tasks. That means teams can spend less time buil
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)2.10.2026 12:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to one senior leader and ten newly hired non-executive employees. The equity awards for the senior leader were granted on September 30, 2026 and consisted of options to purchase an aggregate of 121,800 shares and restricted share units covering an aggregate of 58,000 shares. The options have an exercise price per share equal to $12.44. The equity awards to the ten newly hired non-executive employees were granted on October 1, 2026 and consisted of options to purchase an aggregate of 97,100 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 46,200 shares. These options have an exercise price per share equal to $11.95, the closing price of the Company’s American De
Global Health Leaders to Convene at Abu Dhabi Future Health Summit 20262.10.2026 12:24:00 CEST | Press release
Abu Dhabi Future Health Summit will convene leaders across healthcare, science, technology, policy, and investment from 20-22October at ADNEC Centre Abu DhabiUnder the 2026 theme ‘To Sense is to Predict’, the Future Health Summit will examine how greater health insight can enable earlier intervention and better outcomesAstraZeneca CEO Sir Pascal Soriot, Isomorphic Labs President Mr. Max Jaderberg, Amref Health Africa Group CEO Dr. Githinji Gitahi, and Health Ministers from Kosovo, Montenegro, Serbia and Colombia are among more than 130 Forum speakers, with participation expected from 100 countries Global leaders across healthcare, science, technology, policy, and investment will convene at the Abu Dhabi Future Health Summit from 20 to 22 October 2026 to examine how health systems can better anticipate risk and enable earlier intervention as advances in AI, genomics, diagnostics, and health data create new possibilities for understanding health risks earlier. This press release features
Venture Global and ConocoPhillips Announce 20-Year LNG Sales and Purchase Agreement1.10.2026 22:30:00 CEST | Press release
Today, Venture Global, Inc. (NYSE: VG) and ConocoPhillips (NYSE: COP) announced a new, long-term Sales and Purchase Agreement (SPA) for liquefied natural gas (LNG). Under the SPA, ConocoPhillips will buy 1.0 million tonnes per annum (MTPA) of LNG from Venture Global for 20 years, starting in 2030. "Venture Global is proud to welcome ConocoPhillips, one of the world's leading energy companies, as a long-term partner," said Venture Global CEO Mike Sabel. "This agreement reflects continued market confidence in our proven ability to deliver reliable, low-cost U.S. LNG quickly and at scale. We look forward to supporting ConocoPhillips' growing global LNG portfolio for decades to come." About Venture Global Venture Global is an American producer and exporter of low-cost U.S. liquefied natural gas (LNG) with over 100 MTPA of capacity in production, construction, or development. Venture Global began producing LNG from its first facility in 2022 and is now one of the largest LNG exporters in th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
